Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first of 100 subjects were dosed in an open-label bridging study of AKS-452, its protein subunit Covid-19 vaccine candidate, in India.
AKS-452 is shelf stable for at least six months at room temperatures (up to 25
